Drug Profile
Anti-COVID-19 immunoglobulin - Kamada
Alternative Names: Anti-corona (COVID-19) hyperimmune polyclonal immunoglobulin - Kamada; Anti-Corona (COVID-19) IgG - Kamada; Anti-Corona (COVID-19) polyclonal immunoglobulin - Kamada; Kamada Anti-SARS-CoV-2; Plasma-derived Anti-SARS-CoV-2 IgG - KamadaLatest Information Update: 19 May 2023
Price :
$50
*
At a glance
- Originator Kamada
- Class Antivirals; Immunoglobulins; Polyclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued COVID 2019 infections; COVID-19 pneumonia
Most Recent Events
- 31 Dec 2022 Discontinued - Phase-I/II for COVID-19 pneumonia in Israel (IV) as of December 2022
- 31 Dec 2022 Discontinued for COVID-2019 infections in USA (unspecified route) as of December 2022
- 31 Mar 2021 Topline therapeutic efficacy, adverse events, pharmacodynamics data from a phase I/II trial in COVID-2019 pneumonia released by Kamada